What the FDA labels say about taking them together
Belatacept and cyclosporine
Belatacept's FDA label of July 28, 2021 names cyclosporine in its drug interactions section; the cyclosporine labels PlainMeds reads (4) do not name belatacept. The belatacept label: “… mycophenolate mofetil (MMF) dosage when a patient’s therapy is switched between cyclosporine and NULOJIX, as cyclosporine decreases mycophenolic acid (MPA) exposure by preventing enterohepatic recirculation of MPA while …”
Check it at the source: the belatacept FDA label on DailyMed (effective July 28, 2021, E.R. Squibb & Sons, L.L.C.); the cyclosporine FDA label on DailyMed (effective August 10, 2026, Novartis Pharmaceuticals Corporation).
What does the belatacept label say about cyclosporine?
Belatacept label, drug interactionsDRUG INTERACTIONS 7.1 Mycophenolate Mofetil (MMF) Monitor for a need to adjust concomitant mycophenolate mofetil (MMF) dosage when a patient’s therapy is switched between cyclosporine and NULOJIX, as cyclosporine decreases mycophenolic acid (MPA) exposure by preventing enterohepatic recirculation of MPA while NULOJIX does not [see Clinical Pharmacology (12.3) ]:
Belatacept label, warnings and precautionsTuberculosis Tuberculosis was more frequently observed in patients receiving NULOJIX than cyclosporine in clinical trials [see Adverse Reactions (6.1) ].
Source: FDA drug label (NULOJIX), E.R. Squibb & Sons, L.L.C., effective July 28, 2021 (SPL set c16ac648-d5d2-9f7d-8637-e2328572754e), via openFDA; the full label on DailyMed
What does the cyclosporine label say about belatacept?
Cyclosporine's label (effective August 10, 2026) and its 3 other brand-application labels do not name belatacept in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Neoral), Novartis Pharmaceuticals Corporation, effective August 10, 2026 (SPL set 94461af3-11f1-4670-95d4-2965b9538ae3), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Belatacept | Cyclosporine | |
|---|---|---|
| Labeled for | Organ transplant rejection | Organ transplant rejection, Rheumatoid arthritis |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | n/a | $1.04 per unit 0.05% eye emulsion |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once